NUXA Diagnostics
On-site molecular diagnostics for any disease.
The founders
PB
The company
NUXA Diagnostics is developing an on-site molecular diagnostics platform that aims to deliver results in under 30 minutes, instead of the days a central lab can take. The system uses a prokaryotic Argonaute protein guided by a short RNA sequence to detect the DNA or RNA of a target disease — isothermal, one-pot, and designed to run in the field without lab equipment.
Central-lab PCR still means shipping samples and waiting days, with trained staff required at every step. NUXA's approach is built to drop that to minutes on-site, at what the company says is a fraction of PCR cost — and a new guide for a different disease can reportedly be designed within days.
NUXA is a future spin-off from Wageningen University, building on Argonaute-based detection inspired by the bacterial immune system. The company is founded by Patrick Barendse; beyond that, specifics on the founding team's pedigree aren't yet public.
As a Wageningen University spin-out, NUXA is rooted in one of Europe's strongest life-sciences research bases, which fits a deep-tech diagnostics play. The real test will be moving the platform from lab-validated chemistry to reliable field deployment across its target sectors.
Who else is building in this space
Companies working on the same thing, at every stage.
Unicorn
Developing a new generation of nanopore-based electronic systems for analysis of single molecules
Unicorn
Helping people access, understand, and benefit from the human genome
Unicorn
A clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery
Scale-up
A company focused on the advancement of universal access to genomic information by delivering an affordable, scalable, and accurate genomic sequencing ecosystem that empowers both academic and clinical research applications
Scale-up
Develops diagnostic systems to reduce the cost and improve the efficacy of personalised medical treatments
Scale-up
Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies
Thousands more founded every month.
Dealroom tracks new companies as they appear — founders, funding and signals, over the API or in the platform.